Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports

被引：0
|
作者：
Zullo, Lodovica [1 ,2 ]
Castanet, Elora [3 ]
Maaradji, Zineb [4 ]
Ghigna, Maria Rosa [5 ]
Bonhomme, Benjamin [6 ]
Alame, Melissa [6 ]
Besse, Benjamin [1 ,7 ]
Cousin, Sophie [3 ]
Aldea, Mihaela [1 ,7 ]
机构：
[1] Gustave Roussy, Dept Canc Med, Thorac Canc Unit, Villejuif, France
[2] Univ Genoa, Dept Expt Med DIMES, Genoa, Italy
[3] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[4] Hop Europeen Georges Pompidou, Dept Thorac Oncol, Paris, France
[5] Gustave Roussy, Dept Pathol, Villejuif, France
[6] Inst Bergonie, Dept Biopathol, Bordeaux, France
[7] Paris Saclay Univ, Le Kremlin Bicetre, France
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
ADENOCARCINOMAS; TRANSFORM;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
    van Veggel, B.
    van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    De Langen, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
    Van Veggel, B.
    Van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Schuuring, E.
    Smit, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S815
  • [33] EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
    Kilickap, Saadettin
    NOBEL MEDICUS, 2018, 14 (03): : 5 - 8
  • [34] Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) : 3235 - 3242
  • [35] Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
    Kotsakis, Athanasios
    Georgoulias, Vassilis
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) : 2363 - 2389
  • [36] Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors
    Masahiro Tsuboi
    Thierry Le Chevalier
    Medical Oncology, 2006, 23 : 161 - 170
  • [37] Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
    Tomaras, D.
    Lin, H. M.
    Forsythe, A.
    Crossland, V.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2020, 31 : S871 - S871
  • [38] Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors
    Tsuboi, M
    Le Chevalier, T
    MEDICAL ONCOLOGY, 2006, 23 (02) : 161 - 170
  • [39] Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
    Trigo, J.
    Cho, B. C.
    Park, K.
    Girard, N.
    Viteri, S.
    Garrido, P.
    Krebs, M. G.
    Thayu, M.
    Knoblauch, R. E.
    Xie, J.
    Bauml, J. M.
    Schnepp, R. W.
    Londhe, A.
    Mahadevia, P.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S39
  • [40] Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
    Girard, N.
    Park, K.
    Viteri, S.
    Schioppa, C. A.
    Diels, J.
    Oguz, M.
    Rodrigues, B. H.
    Rahhali, N.
    Sermon, J.
    Ghilotti, F.
    Li, T.
    Knoblauch, R. E.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S38
12345